» Authors » Derseree Archary

Derseree Archary

Explore the profile of Derseree Archary including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 42
Citations 1098
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Maseko T, Rambaran S, Ngubane S, Lewis L, Ngcapu S, Hassan-Moosa R, et al.
Sci Rep . 2023 Jul; 13(1):11726. PMID: 37474556
Natural killer (NK) cells, key effector cells of the innate immune system, play an important role in the clearance and control of Mycobacterium tuberculosis and HIV infections. Here, we utilized...
12.
Mahomed S, Garrett N, Capparelli E, Osman F, Mkhize N, Harkoo I, et al.
Lancet HIV . 2023 Mar; 10(4):e230-e243. PMID: 37001964
Background: Young women in sub-Saharan Africa continue to bear a high burden of HIV infection. Combination anti-HIV monoclonal antibodies are a potential HIV prevention technology that could overcome adherence challenges...
13.
Abdool Karim Q, Archary D, Barre-Sinoussi F, Broliden K, Cabrera C, Chiodi F, et al.
Front Immunol . 2022 Dec; 13:1055042. PMID: 36561760
Preventing new HIV infections remains a global challenge. Young women continue to bear a disproportionate burden of infection. Oral pre-exposure prophylaxis (PrEP), offers a novel women-initiated prevention technology and PrEP...
14.
Lustig G, Ganga Y, Rodel H, Tegally H, Jackson L, Cele S, et al.
medRxiv . 2022 Dec; PMID: 36451879
The milder clinical manifestations of Omicron infection relative to pre-Omicron SARS CoV-2 raises the possibility that extensive evolution results in reduced pathogenicity. To test this hypothesis, we quantified induction of...
15.
Zondo N, Sobia P, Sivro A, Ngcapu S, Ramsuran V, Archary D
Front Genet . 2022 Oct; 13:940661. PMID: 36246609
The use of antiretrovirals (ARVs) as oral, topical, or long-acting pre-exposure prophylaxis (PrEP) has emerged as a promising strategy for HIV prevention. Clinical trials testing Truvada [tenofovir disoproxil fumarate (TDF)/tenofovir...
16.
Mazibuko-Motau N, Sobia P, Xu J, Elsherbini J, San J, Lewis L, et al.
Sci Rep . 2022 Sep; 12(1):16187. PMID: 36171447
Vaginal microbiota have been shown to be a modifier of protection offered by topical tenofovir in preventing HIV infection in women, an effect not observed with oral tenofovir-based pre-exposure prophylaxis...
17.
Liebenberg L, Passmore J, Osman F, Jewanraj J, Mtshali A, Garcia-Lerma J, et al.
Clin Infect Dis . 2022 Feb; 75(6):1088-1091. PMID: 35142337
Genital inflammation (GI) undermines topical human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) efficacy through unknown mechanisms. Here, associations between activated endocervical CD4 + T-cell numbers and higher deoxyadenosine triphosphate (dATP)...
18.
Mahomed S, Garrett N, Capparelli E, Osman F, Harkoo I, Yende-Zuma N, et al.
J Infect Dis . 2022 Feb; 226(3):510-520. PMID: 35134995
Background: Effective, long-acting prevention approaches are needed to reduce human immunodeficiency virus (HIV) incidence. We evaluated the safety and pharmacokinetics of VRC07-523LS and PGT121 administered subcutaneously alone and in combination...
19.
Cele S, Jackson L, Khoury D, Khan K, Moyo-Gwete T, Tegally H, et al.
Nature . 2022 Jan; 602(7898):654-656. PMID: 35016196
The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B.1.1.529), first identified in Botswana and South Africa, may compromise vaccine effectiveness and lead to re-infections. Here we investigated...
20.
Cele S, Jackson L, Khoury D, Khan K, Moyo-Gwete T, Tegally H, et al.
medRxiv . 2021 Dec; PMID: 34909788
The emergence of SARS-CoV-2 Omicron, first identified in Botswana and South Africa, may compromise vaccine effectiveness and the ability of antibodies triggered by previous infection to protect against re-infection (1)....